Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS greater than or equal to 1.5).

Trial Profile

Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS greater than or equal to 1.5).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 May 2014

At a glance

  • Drugs Laromustine (Primary) ; Amsacrine; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms HOVON-92-AML
  • Most Recent Events

    • 15 Mar 2012 This trial has been completed in Belgium and discontinued in Netherlands as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual initiation date (Sep 2008) added as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned End Date changed from 30 Sep 2012 to 12 Apr 2013 as reported by European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top